Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: A study of 15 990 patients

Journal of Human Hypertension

Volumn 28, Issue 11, 2014, Pages 663-669

  Hasvold, L P ^a,b   Bodegard J ^b,c   Thuresson, M ^d   Stalhammar J ^e   Hammar, N ^f,g   Sundstrom J ^h   Russell, D ⁱ   Kjeldsen, S E ⁱ  

^a UNIVERSITY OF OSLO   (Norway)

^b ASTRAZENECA   (United Kingdom)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d STATISTICON AB   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g ASTRAZENECA R AND D   (Sweden)

^h UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHOLESTEROL; CREATININE; ENALAPRIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; ICD-10; ICD-9; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; RISK FACTOR; SWEDEN; TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924269487     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.43     Document Type: Article

References (27)

1. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
2. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
3. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008; 6: 1195-1201.
4. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
5. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207.
6. Chen CC, Chiang AN, Hsieh MH. Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus Diabetes Res Clin Pract 2010; 90: e25-e26.
7. Manrique C, Lastra G, Sowers JR. New insights into insulin action and resistance in the vasculature. Ann NY Acad Sci 2014; 311: 136-156.
8. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
9. ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
10. Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010; 24: 263-273.
11. Martinell M, Stalhammar J, Hallqvist J. Automated data extraction-a feasible way to construct patient registers of primary care utilization. Ups J Med Sci 2012; 117: 52-56.
12. Ludvigsson JF, Andersson A, Ekbom A, Feychting M, Kim J-L, Reuterwall C et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
13. Rolandsson O, Norberg M, Nyström L, Sö derberg S, Svensson M, Lindahl B et al. How to diagnose and classify diabetes in primary health care: lessons learned from the Diabetes Register in Northern Sweden (DiabNorth). Scand J Primary Health Care 2012; 30: 81-87.
14. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyö rälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004; 27: 2898-2904.
15. Novak M, Bjö rck L, Giang KW, Heden-Ståhl C, Wilhelmsen L, Rosengren A. Perceived stress and incidence of Type 2 diabetes: a 35-year follow-up study of middle-aged Swedish men. Diabet Med 2013; 30: e8-e16.
16. Agardh E, Allebeck P, Hallqvist P, Tahereh Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis Int. J Epidemiol 2011; 40: 804-818.
17. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 11: 987-1003.
18. Tiikkaja S, Olsson M, Malki N, Modin B, Sparén P. Familial risk of premature cardiovascular mortality and the impact of intergenerational occupational class mobility. Soc Sci Med 2012; 75: 1883-1890.
19. Brookhart MA, Wyss R, Layton JB, Stü rmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6: 604-611.
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
21. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150-161.
22. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization. J Stat Software 2011; 42: 1-52.
23. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809-848.
24. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovasc Diabetol 2009; 8: 18.
25. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
26. Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens 2007; 9: 692-700.
27. Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group J Hum Hypertens 1999; 13: 413-417.